Citations

Clear

3942 citation(s) found for "To, Van".

Increased Operative Time for Benign Cranial Nerve Tumor Resection Correlates with Increased Morbidity Postoperatively
Murphy, Meghan E. , Gilder, Hannah E., McCutcheon, Brandon A., Kerezoudis, Panagiotis , Rinaldo, Lorenzo , Shepherd, Daniel , Maloney, Patrick R. , Snyder, Kendall, Carlson, Matthew L. , Link, Michael J., Bydon, Mohamad , Murphy, Meghan, Gilder, Hannah, Maloney, Patrick , Van Gompel, Jamie J, Carter, Bob S. , Gompel, Jamie J. Van

Mayo Clinic

Journal of Neurological Surgery Part B: Skull Base | February 13, 2016 | Volume: 77 | Issue: 04 | Pages: 350-357

10.1055/s-0036-1572508 | PMID 27441161 Get It

Primary Pseudomyogenic Hemangioendothelioma of Bone
Inyang, Alero F., Mertens, Fredrik , Puls, Florian , Vaiyapuri, Sumathi , Inwards, Carrie Y., Folpe, Andrew L. , Zhang, Yaxia , Symmans, Pennie, Nielsen, G. Petur , Nguyễn, Văn Hùng , Rosenberg, Andrew E. , Inyang, Alero, Lee, Cheng‐Han , Rubin, Brian P.

Mayo Clinic

American Journal of Surgical Pathology | February 12, 2016 | Volume: 40 | Issue: 5 | Pages: 587-598

10.1097/pas.0000000000000613 | PMID 26872012 Get It

Pseudomyogenic hemangioendothelioma (PMH) is a well-recognized neoplasm that usually arises in the soft tissue; concurrent bone involvement occurs in 24% of cases. PMH of bone without soft tissue involvement is rare. We describe the clinicopathologic findings of 10 such cases, the largest series reported to date. The study included 9 male and 1 female patient; their ages ranged from 12 to 74 years (mean 36.7 y). All patients had multiple tumors with a distinct regional distribution: 45% restricted to the lower extremity; 25% to the spine and pelvis; and 15% to the upper extremity. On imaging studies the tumors were well circumscribed and lytic. The neoplasms were composed of spindled cells arranged in intersecting fascicles with scattered epithelioid cells; epithelioid cells predominated in 3 cases. The neoplastic cells contained abundant densely eosinophilic cytoplasm and vesicular nuclei. There was limited cytologic atypia and necrosis, few mitoses (0 to 2/10 high-power fields), and inconspicuous stroma. Unique findings included abundant intratumoral reactive woven bone and hemorrhage with numerous osteoclast-like giant cells. Immunohistochemically, most tumors were positive for keratin, ERG, and CD31; CD34 was negative. The balanced t(7:19)(q22;13) translocation was documented in 3 cases. Follow-up is limited, but no patient developed documented visceral dissemination, and all have stable or progressive osseous disease. PMH exclusively involving bone is rare. It is multicentric, often involves the lower extremity, and has unusual morphology. The differential diagnosis includes epithelioid vascular neoplasms, giant cell tumor, bone forming neoplasms, and metastatic carcinoma. Because of its rarity, unusual presentation, and morphology, accurate diagnosis can be challenging.
Determinants of Early Mortality Among 37,568 Patients With Colon Cancer Who Participated in 25 Clinical Trials From the Adjuvant Colon Cancer Endpoints Database
Renfro, Lindsay A. , Kerr, David , Gramont, Aimery de , André, Thierry , Guthrie, Katherine A. , Labianca, Roberto , Francini, Guido, Seitz, J. F., O’Callaghan, Chris J. , Twelves, Chris , Haller, Daniel G. , Yothers, Greg , Cheung, Winson Y, de Gramont, Aimery, Saltz, Leonard B. , O'Callaghan, Chris, van Cutsem, Eric, Cheung, Winson Y. , Grothey, Axel , Alberts, Steven R. , Cutsem, Eric Van , Sargent, Daniel J. , André, Thierry , Yothers, Greg

Mayo Clinic

Journal of Clinical Oncology | February 9, 2016 | Volume: 34 | Issue: 11 | Pages: 1182-1189

10.1200/jco.2015.65.1158 | PMID 26858337 Get It

Purpose Factors associated with early mortality after surgery and treatment with adjuvant chemotherapy in colon cancer are poorly understood. We aimed to characterize the determinants of early mortality in a large cohort of colon cancer trial participants. Methods A pooled analysis of 37,568 patients in 25 randomized trials of adjuvant systemic therapy was conducted. Multivariable logistic regression models with several definitions of early mortality (30, 60, and 90 days, and 6 months) were constructed, adjusting for clinically and statistically significant variables. A nomogram for 6-month mortality was developed and validated. Results Median age among patients was 61 years, patient demographics included 54% men and 90% White, 29% and 71% had stage II and III disease, respectively, and 79%, 20%, and 1% had an Eastern Cooperative Oncology Group performance status (PS) of 0, 1, and ≥ 2, respectively. Early mortality was low: 0.3% at 30 days, 0.6% at 60 days, 0.8% at 90 days, and 1.4% at 6 months. Of those patients who died by 6 months post–random assignment, 40% had documented disease recurrence prior to death. Early disease recurrence was associated with a markedly increased risk of death during the first 6 months post-treatment (hazard ratio, 82.6; 95%CI, 66.9 to 102.1). In prognostic analyses, advanced age, male sex, poorer PS, increasing ratio of positive to examined lymph nodes, earlier decade of enrollment, and higher tumor stage and grade predicted a greater likelihood of early mortality, whereas treatment received was not strongly predictive. A multivariable model for 6-month mortality showed strong optimism-adjusted discrimination (concordance index, 0.73) and calibration. Conclusion Early mortality was infrequent but more prevalent in patients with advanced age and a PS of ≥ 2, underscoring the need to carefully consider the risk-to-benefit ratio when making treatment decisions in these subgroups.
The Dohner fluorescence in situ hybridization prognostic classification of chronic lymphocytic leukaemia (CLL): the CLL Research Consortium experience
Dyke, Daniel L. Van , Werner, Lillian , Rassenti, Laura Z., Ghia, Emanuella, Heerema, Nyla A. , Cin, Paola Dal , Aquila, Marie Dell, Sreekantaiah, Chandrika, Greaves, Andrew, Van Dyke, Daniel L, Neuberg, Donna , Kipps, Thomas J. , Kay, Neil E.

Mayo Clinic

British Journal of Haematology | February 5, 2016 | Volume: 173 | Issue: 1 | Pages: 105-113

10.1111/bjh.13933 | PMID 26848054 Get It

SummaryThis study revisited the Dohner prognostic hierarchy in a cohort of 1585 well‐documented patients with chronic lymphocytic leukaemia. The duration of both time to first treatment (TTFT) and overall survival (OS) were significantly longer than observed previously, and this is at least partly due to improved therapeutic options. Deletion 13q remains the most favourable prognostic group with median TTFT and OS from fluorescence in situ hybridization (FISH) testing of 72 months and >12 years, respectively. Deletion 11q had the poorest median TTFT (22 months) and 17p deletion the poorest median OS (5 years). The percentages of abnormal nuclei were significantly associated with differential TTFT for the trisomy 12, 13q and 17p deletion cohorts but not for the 11q deletion cohort. From the date of the first FISH study, patients with >85% 13q deletion nuclei had a notably shorter TTFT (24 months). Patients with ≤20% 17p deletion nuclei had longer median TTFT and OS from the date of the first FISH study (44 months and 11 years), and were more likely to be IGHV mutated.
Clinical delineation of the PACS1‐related syndrome—Report on 19 patients
Schuurs-Hoeijmakers, Janneke , Landsverk, Megan , Foulds, Nicola , Kukolich, Mary K. , Gavrilova, Ralitza H. , Greville‐Heygate, Stephanie , Hanson‐Kahn, Andrea , Bernstein, Jonathan A. , Glass, Jennifer, Burrow, Thomas Andrew, Husami, Ammar , Collins, Kathleen , Wusik, Katie, Aa, Nathalie Van der, Kooy, R. Frank , Brown, Kate Tatton, Gadzicki, Dorothea, Kini, Usha , McGehee, Frank T., Selby, Katherine, Tarailo‐Graovac, Maja , Allen, Margot Van, Stavropoulos, Dimitri J. , Marshall, Christian R. , Merico, Daniele , Gregor, Anne , Zweier, Christiane , Chu, Yoyo W. Y., Vries, Bert B.A. de , Brunner, Han G. , study, DDD, Chitayat, David A. , Collins, Kathleen , Álvarez, Sara , Fernández‐Jaén, Alberto , Allen, Margot I. Van, Karnebeek, Clara van , Hopkin, Robert J. , Chung, Hon-Yin B , Devriendt, Koenraad , Hurles, Matthew E. , study, DDD, Kooy, Frank , de Vries, Bert B A , Marshall, Christian R.

Mayo Clinic

American Journal of Medical Genetics Part A | February 4, 2016 | Volume: 170 | Issue: 3 | Pages: 670-675

10.1002/ajmg.a.37476 | PMID 26842493 Get It

We report on 19 individuals with a recurrent de novo c.607C>T mutation in PACS1. This specific mutation gives rise to a recognizable intellectual disability syndrome. There is a distinctive facial appearance (19/19), characterized by full and arched eyebrows, hypertelorism with downslanting palpebral fissures, long eye lashes, ptosis, low set and simple ears, bulbous nasal tip, wide mouth with downturned corners and a thin upper lip with an unusual “wavy” profile, flat philtrum, and diastema of the teeth. Intellectual disability, ranging from mild to moderate, was present in all. Hypotonia is common in infancy (8/19). Seizures are frequent (12/19) and respond well to anticonvulsive medication. Structural malformations are common, including heart (10/19), brain (12/16), eye (10/19), kidney (3/19), and cryptorchidism (6/12 males). Feeding dysfunction is presenting in infancy with failure to thrive (5/19), gastroesophageal reflux (6/19), and gastrostomy tube placement (4/19). There is persistence of oral motor dysfunction. We provide suggestions for clinical work‐up and management and hope that the present study will facilitate clinical recognition of further cases. © 2016 Wiley Periodicals, Inc.
Cerebellar ataxia in progressive supranuclear palsy: An autopsy study of PSP‐C
Koga, Shunsuke , Josephs, Keith A. , Ogaki, Kotaro, Uitti, Ryan J. , Graff‐Radford, Neill R. , Gerpen, Jay A. van, Cheshire, William P. , Aoki, Naoya , Rademakers, Rosa , Ross, Owen A. , Labbé, Catherine, Van Gerpen, Jay A, Labbé, Catherine , Wszołek, Zbigniew K. , Dickson, Dennis W. , Koga, Shunsuke , Cheshire, William P , Ross, Owen A

Mayo Clinic

Movement Disorders | February 3, 2016 | Volume: 31 | Issue: 5 | Pages: 653-662

10.1002/mds.26499 | PMID 26841329 Get It

ABSTRACTBackgroundCerebellar ataxia is an exclusion criterion for the clinical diagnosis of progressive supranuclear palsy, but a variant with predominant cerebellar ataxia has been reported. The aims of this study were to estimate the frequency of progressive supranuclear palsy with predominant cerebellar ataxia in an autopsy series from the United States and to compare clinical, pathologic, and genetic differences between progressive supranuclear palsy with and without predominant cerebellar ataxia.MethodWe selected 100 consecutive patients with pathologically confirmed progressive supranuclear palsy who had been evaluated at the Mayo Clinic (referred to as the Mayo Clinic patient series) from our brain bank database (N = 1085). We next enriched in cases likely to have cerebellar ataxia by searching the remaining 985 cases for (1) an antemortem diagnosis of multiple system atrophy or (2) neuropathologic evidence of prominent degeneration of the cerebellum or cerebellar afferent nuclei. Subsequently, clinical, pathologic, and genetic features were compared between the two groups.ResultsOne patient in the Mayo Clinic patient series (1%) met criteria for progressive supranuclear palsy with predominant cerebellar ataxia and had both cerebellar and mild midbrain atrophy on MRI. Four patients were identified with the targeted search. Four of the five patients were clinically misdiagnosed as multiple system atrophy. The severity of tau‐related pathology and cerebellar degeneration were not different between the two groups. No differences were detected in tau genotypes.ConclusionAlthough our data cannot provide definitive information about how to make an accurate clinical diagnosis, they should serve to raise awareness of progressive supranuclear palsy with predominant cerebellar ataxia in the differential diagnosis of multiple system atrophy. © 2016 Movement Disorder Society
A targeted genetic association study of epithelial ovarian cancer susceptibility
Earp, Madalene A. , Winham, Stacey J. , Sicotte, Hugues , Chien, Jeremy , Goodman, Marc T. , Levine, Douglas A. , Monteiro, Álvaro N.A. , Ness, Roberta B., Pearce, Celeste Leigh, Rossing, Mary Anne, Tworoger, Shelley S. , Wentzensen, Nicolas , Bisogna, Maria, Brinton, Louise A. , Brooks‐Wilson, Angela , Carney, Michael E. , Cunningham, Julie M. , Edwards, Robert P., Fogarty, Zachary C. , Iversen, Edwin S., Kraft, Peter , Le, Nhu D. , Lin, Hui‐Yi , Lissowska, Jolanta , Moysich, Kirsten B. , Olson, Sara H. , Pike, Malcolm C. , Rider, David N., Terry, Kathryn L. , Thompson, Pamela J., Vierkant, Robert A. , Vitonis, Allison F., Wu, Anna H. , Phelan, Catherine M., Schildkraut, Joellen M. , Chen, Y. Ann , Sellers, Thomas A. , Goode, Ellen L. , Earp, Madalene, Larson, Nicholas, Larson, Nicholas B. , Permuth, Jennifer B. , Anton‐Culver, Hoda , Bandera, Elisa V. , Berchuck, Andrew , Cook, Linda S. , Cramer, Daniel W. , Doherty, Jennifer A. , Larson, Melissa C. , Modugno, Francesmary , Poole, Elizabeth M. , Berg, David Van Den , Wilkens, Lynne R. , Yang, Hannah , Ziogas, Argyrios , Fridley, Brooke L. , Winham, Stacey J , Tworoger, Shelley S , Vierkant, Robert A , Chien, Jeremey , Monteiro, Alvaro N , Moysich, Kirsten , Lissowska, Jolanta , Brooks-Wilson, Angela R , Lin, Hui-Yi , Fogarty, Zachary C , Kraft, Peter , Goodman, Marc T

Mayo Clinic

Oncotarget | February 2, 2016 | Volume: 7 | Issue: 7 | Pages: 7381-7389

10.18632/oncotarget.7121 | PMID 26848776 Get It

Mutations in TSC1, TSC2, and MTOR Are Associated with Response to Rapalogs in Patients with Metastatic Renal Cell Carcinoma
Choueiri, Toni K. , Fay, André P. , Velasco, Guillermo de , Tyburczy, Magdalena E. , Hamieh, Lana , Albigès, Laurence , Ho, Thai H. , Song, Jiaxi , Pignon, Jean‐Christophe , Barrios, Pablo M. , Michaelson, M. Dror , Krajewski, Katherine M. , Porta, Camillo , Pal, Sumanta K. , Heng, Daniel Y.C., Gray, Kathryn P. , Kwiatkowski, David J. , Rini, Brian I. , Thorner, Aaron R. , Agarwal, Neeraj , Van Allen, Eliezer M , Bellmunt, Joaquim , McDermott, David F. , Signoretti, Sabina , Ho, Thai , Choueiri, Toni K

Mayo Clinic

Clinical Cancer Research | February 1, 2016 | Volume: 22 | Issue: 10 | Pages: 2445-2452

10.1158/1078-0432.ccr-15-2631 | PMID 26831717 Get It

Abstract Purpose: We examined the hypothesis that mutations in mTOR pathway genes are associated with response to rapalogs in metastatic renal cell carcinoma (mRCC). Experimental Design: We studied a cohort of mRCC patients who were treated with mTOR inhibitors with distinct clinical outcomes. Tumor DNA from 79 subjects was successfully analyzed for mutations using targeted next-generation sequencing of 560 cancer genes. Responders were defined as those with partial response (PR) by RECIST v1.0 or stable disease with any tumor shrinkage for 6 months or longer. Nonresponders were defined as those with disease progression during the first 3 months of therapy. Fisher exact test assessed the association between mutation status in mTOR pathway genes and treatment response. Results: Mutations in MTOR, TSC1, or TSC2 were more common in responders, 12 (28%) of 43, than nonresponders, 4 (11%) of 36 (P = 0.06). Mutations in TSC1 or TSC2 alone were also more common in responders, 9 (21%), than nonresponders, 2(6%), (P = 0.05). Furthermore, 5 (42%) of 12 subjects with PR had mutations in MTOR, TSC1, or TSC2 compared with 4 (11%) of 36 nonresponders (P = 0.03). Eight additional non-mTOR pathway genes were found to be mutated in at least 4 of 79 tumors (5%); none were associated positively with response. Conclusions: In this cohort of mRCC patients, mutations in MTOR, TSC1, or TSC2 were more common in patients who experienced clinical benefit from rapalogs than in those who progressed. However, a substantial fraction of responders (24 of 43, 56%) had no mTOR pathway mutation identified. Clin Cancer Res; 22(10); 2445–52. ©2016 AACR. See related commentary by Voss and Hsieh, p. 2320
Germline polymorphisms in an enhancer of PSIP1 are associated with progression-free survival in epithelial ovarian cancer
Group, Australian Ovarian Cancer Study, Study, Australian Cancer, Johnatty, Sharon E. , Lu, Yi , Beesley, Jonathan, Gao, Bo , Kalimutho, Murugan , Henderson, Michelle J. , Russell, Amanda J. , Kar, Siddhartha , Chen, Xiaoqing, Hillman, Kristine M. , Kaufmann, Susanne, Sivakumaran, Haran , O’Reilly, Martin, Wang, Chen , Korbie, Darren , Lambrechts, Diether , Despierre, Evelyn, Nieuwenhuysen, Els Van , Lambrechts, Sandrina, Vergote, Ignace , Lester, Jenny, Oršulić, Sandra , Walsh, Christine M. , Fasching, Peter A. , Beckmann, Matthias W. , Ekici, Arif B. , Hein, Alexander , Matsuo, Keitaro , Hosono, Satoyo , Pisterer, Jacobus, Hillemanns, Peter , Nakanishi, Toru , Yatabe, Yasushi , Goodman, Marc T. , Lurie, Galina, Matsuno, Rayna K., Thompson, Pamela J., Bean, Yukie T., Heitz, Florian , Harter, Philipp , Schwaab, Ira, Høgdall, Estrid , Jensen, Allan , Høgdall, Claus , Lundvall, Lene, Engelholm, Svend Aage, Brown, Bob, Flanagan, James M. , Metcalf, Michelle, Sellers, Thomas A. , Cunningham, Julie M. , Schildkraut, Joellen M. , Iversen, Ed , Weber, Rachel Palmieri , Brennan, Donal J. , Harnett, Paul R. , Haber, Michelle , Goode, Ellen L. , Lee, Jason S. , Khanna, Kum Kum , Meyer, Kerstin B. , Chenevix‐Trench, Georgia , DeFazio, Anna , Edwards, Stacey L. , MacGregor, Stuart , Brown, Robert , Lambrechts, Diether , Cunningham, Julie, Fazio, Anna de , French, Juliet D. , Group, Australian Ovarian Cancer Study, Study, Australian Cancer, Beesley, Jonathan, Chen, Xiaoqing, Karlan, Beth Y. , Pejovic, Tanja B. , Bois, Andreas du , Kjær, Susanne K. , Brown, Bob, Siddiqui, Nadeem , Fridley, Brooke L. , Berchuck, Andrew , Pharoah, Paul D.P. , Norris, Murray D , Lambrechts, Diether , Hein, Alexander , Hillemanns, Peter , Jensen, Allan , Haber, Michelle , Wang, Chen , Brown, Robert , Matsuo, Keitaro , Flanagan, James M , Heitz, Florian , Lambrechts, Diether , Ekici, Arif B , Lu, Yi , MacGregor, Stuart , Chenevix-Trench, Georgia , Høgdall, Estrid , Høgdall, Claus K , Kar, Siddhartha , Harnett, Paul R , Goodman, Marc T

Mayo Clinic

Oncotarget | January 31, 2016 | Volume: 7 | Issue: 6 | Pages: 6353-6368

10.18632/oncotarget.7047 | PMID 26840454 Get It

Effectiveness of rosiglitazone in reducing flexion contracture in a rabbit model of arthrofibrosis with surgical capsular release
Arsoy, Diren , Riester, Scott M. , Wijnen, André J. van , Morrey, B.F. , Barlow, Jonathan D. , Morrey, Mark E. , Hartzler, Robert U. , Sánchez‐Sotelo, Joaquín , Abdel, Matthew P. , van Wijnen, Andre J

Mayo Clinic

Bone & Joint Research | January 27, 2016 | Volume: 5 | Issue: 1 | Pages: 11-17

10.1302/2046-3758.51.2000593 | PMID 26813567 Get It

Aims Animal models have been developed that allow simulation of post-traumatic joint contracture. One such model involves contracture-forming surgery followed by surgical capsular release. This model allows testing of antifibrotic agents, such as rosiglitazone. Methods A total of 20 rabbits underwent contracture-forming surgery. Eight weeks later, the animals underwent a surgical capsular release. Ten animals received rosiglitazone (intramuscular initially, then orally). The animals were sacrificed following 16 weeks of free cage mobilisation. The joints were tested biomechanically, and the posterior capsule was assessed histologically and via genetic microarray analysis. Results There was no significant difference in post-traumatic contracture between the rosiglitazone and control groups (33° (standard deviation (sd) 11) vs 37° (sd14), respectively; p = 0.4). There was no difference in number or percentage of myofibroblasts. Importantly, there were ten genes and 17 pathways that were significantly modulated by rosiglitazone in the posterior capsule. Discussion Rosiglitazone significantly altered the genetic expression of the posterior capsular tissue in a rabbit model, with ten genes and 17 pathways demonstrating significant modulation. However, there was no significant effect on biomechanical or histological properties. Cite this article: M. P. Abdel. Effectiveness of rosiglitazone in reducing flexion contracture in a rabbit model of arthrofibrosis with surgical capsular release: A biomechanical, histological, and genetic analysis. Bone Joint Res 2016;5:11–17. doi: 10.1302/2046-3758.51.2000593